theranostics
(2)
Akira Robinson
Akira Robinson is a biotech and pharmaceutical commercialization leader with roughly two decades of experience turning early-stage science into market-ready medicine. He is a Partner and Chief Experience Officer at the life-sciences consultancy Scimitar Inc. and serves as interim Chief Commercial Officer at Nucleus RadioPharma. He built and scaled the launch practice at EVERSANA to more than 20 consultants, and has stepped into interim CCO and COO seats across the industry. With a Harvard biochemistry degree, a Johns Hopkins biotech master's, and a stint as a Wall Street biotech equity analyst, he blends scientific fluency with commercial operating chops, lately focused on radiopharmaceutical therapies and AI-driven commercialization.
Bill Cupelo
Bill Cupelo is the Chief Business Officer of Ratio Therapeutics, a Boston-based biotech building targeted radiopharmaceuticals that aim to both image and treat cancer. A chemist by training who learned to sell science, he spent more than a decade at imaging CRO Invicro, climbing from software product manager to head of sales, before bringing his sponsor-side, science-first mindset to Ratio's pipeline of alpha-emitting radioligand therapies. He also serves as Treasurer of the Massachusetts Nuclear Medicine & Radiopharmaceutical Council.